The Effect of Tear Supplementation with 0.15% Preservative-Free Zinc-Hyaluronate on Ocular Surface Sensations in Patients with Dry Eye

2017 ◽  
Vol 33 (6) ◽  
pp. 487-492 ◽  
Author(s):  
Kristóf Perényi ◽  
Lóránt Dienes ◽  
Anna Kornafeld ◽  
Balázs Kovács ◽  
Huba J. Kiss ◽  
...  
2012 ◽  
Vol 2012 ◽  
pp. 1-16 ◽  
Author(s):  
Frederic Lallemand ◽  
Philippe Daull ◽  
Simon Benita ◽  
Ronald Buggage ◽  
Jean-Sebastien Garrigue

Topical ophthalmic delivery of active ingredients can be achieved using cationic nanoemulsions. In the last decade, Novagali Pharma has successfully developed and marketed Novasorb, an advanced pharmaceutical technology for the treatment of ophthalmic diseases. This paper describes the main steps in the development of cationic nanoemulsions from formulation to evaluation in clinical trials. A major challenge of the formulation work was the selection of a cationic agent with an acceptable safety profile that would ensure a sufficient ocular surface retention time. Then, toxicity and pharmacokinetic studies were performed showing that the cationic emulsions were safe and well tolerated. Even in the absence of an active ingredient, cationic emulsions were observed in preclinical studies to have an inherent benefit on the ocular surface. Moreover, clinical trials demonstrated the efficacy and safety of cationic emulsions loaded with cyclosporine A in patients with dry eye disease. Ongoing studies evaluating latanoprost emulsion in patients with ocular surface disease and glaucoma suggest that the beneficial effects on reducing ocular surface damage may also extend to this patient population. The culmination of these efforts has been the marketing of Cationorm, a preservative-free cationic emulsion indicated for the symptomatic treatment of dry eye.


2018 ◽  
Vol 28 (4) ◽  
pp. 385-392 ◽  
Author(s):  
Anton Hommer ◽  
Doreen Schmidl ◽  
Martina Kromus ◽  
Ahmed M Bata ◽  
Klemens Fondi ◽  
...  

Purpose: Long-term glaucoma therapy with preservative-containing eye drops may impact ocular surface health. This study was performed to investigate whether a switch from preserved topical prostaglandin therapy to preservative-free tafluprost therapy improves precorneal tear film thickness in patients with glaucoma or ocular hypertension. Methods: A total of 30 patients who were under topical preservative-containing prostaglandin monotherapy for at least 6 months were included. Patients were then switched from preserved prostaglandin therapy to unpreserved tafluprost drops once daily. Tear film thickness was measured at baseline and 4 and 12 weeks after therapy change with an ultrahigh-resolution optical coherence tomography system. Furthermore, clinical measures of ocular surface disease were determined and symptoms were assessed using the Dry Eye–Related Quality-of-Life Score. Results: After switching to unpreserved tafluprost, tear film thickness significantly increased from 4.7 ± 0.5 to 5.0 ± 0.6 µm 4 weeks after therapy change and still tended to be increased after 12 weeks (4.8 ± 0.7 µm). Breakup time significantly increased from 5.1 ± 2.3 to 7.2 ± 3.4 s and to 10.1 ± 3.6 s after therapy change. In addition, a significant decrease in corneal staining score from 1.8 ± 0.7 to 1.4 ± 0.8 after 4 weeks and to 0.7 ± 0.7 after 12 weeks treatment was observed. Switching to preservative-free drops reduced Dry Eye–Related Quality-of-Life Score from 11.4 ± 11.0 to 5.7 ± 6.4 and to 4.7 ± 7.5. Conclusion: Our data show that switching to preservative-free tafluprost leads to an increase in tear film thickness, breakup time, and an improvement of Dry Eye–Related Quality-of-Life Score. Our results therefore indicate that a switch to unpreserved tafluprost is beneficial for ocular surface health in patients under long-term preserved prostaglandin eye drops.


2021 ◽  
Author(s):  
Mauricio Aguirre Baez ◽  
Rodrigo Castillo Iturria

Glaucoma treatment is closely related to the appearance or worsening of dry eye symptoms. The current topical treatment produces chronic inflammation that affects globet cells, meibomian glands and cornea, which translates into a decrease in the quantity and quality of the tear. It is characterized by increased osmolarity, which perpetuates damage to the ocular surface. Preservatives currently play a fundamental role in damage the ocular surface. There are numerous studies that have shown their toxic effects on the eye. Currently there are numerous preservative-free formulations and new therapies that allow us to improve the condition of the ocular surface in patients with glaucoma. A rational treatment is proposed using the different approaches available in the literature.


2018 ◽  
Vol 59 (8) ◽  
pp. 3375 ◽  
Author(s):  
Yiran Yang ◽  
Caihong Huang ◽  
Xiang Lin ◽  
Yang Wu ◽  
Weijie Ouyang ◽  
...  

2021 ◽  
pp. 1-9
Author(s):  
Philippe Daull ◽  
Takashi Nagano ◽  
Emilie Gros ◽  
Laurence Feraille ◽  
Stefano Barabino ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document